Showing Results for
- Academic Journals (7)
Search Results
- 7
Academic Journals
- 7
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Francesca Martella [*] aff1 , Carlotta Bacci aff1 , Clara Giordano aff1 , Francesco Montagnani aff1 , Elena Gelain aff2 , Loredana Rabatti aff3 , Luisa Fioretto aff1 KEYWORDS eribulin; metastatic breast...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Marta Gubbiotti aff1 , Barbara Pistilli [*] aff2 , Marianna Tudini aff3 , Giovanni Benedetti aff2 , Eva Galizia aff4 , Marco Rusiello aff2 , Luciano Latini aff2 KEYWORDS brain metastases; breast cancer;...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Karen Borgonovo [*] aff1 , Fausto Petrelli aff1 , Mary Cabiddu aff1 , Mara Ghilardi aff1 , Andrea Coinu aff1 , Silvia Seghezzi aff2 , Sandro Barni aff1 KEYWORDS breast cancer; chemotherapy; eribulin...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Sandro Barni [*] aff1 KEYWORDS breast cancer; case study; erbulin mesylate Breast cancer remains the most common oncological disease in women. Although the diagnostic and therapeutic advantages...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Claudia Casanova [*] aff1 , Alberto Verlicchi aff1 , Valentina Mazza aff1 , Claudio Dazzi aff1 KEYWORDS eribulin mesylate; HER2+ breast cancer patient; trastuzumab The HER2 was identified a quarter...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Luigi Leo [*] aff1 , Francesca Caputo aff1 , Antonella Di Sarno aff1 , Tiziana Garofano aff1 , Francesca Andreozzi aff1 , Maria Grazia Massaro aff1 , Vincenzo Montesarchio aff1 KEYWORDS breast cancer;...
-
From:Future Oncology (Vol. 11, Issue 15s) Peer-ReviewedAuthor(s): Monica Iorfida [*] aff1 , Manuelita Mazza aff1 KEYWORDS breast cancer; eribulin; response Eribulin mesylate (Halaven® , INN: eribulin mesilate, E7389) is a nontaxane microtubule dynamics inhibitor,...